← Issue №18/ week of Nov 1, 2026/Pancreas/Biliary

Screening for Biliary Dysplasia Using Brush Cytology in PSC: Prevalence, Risk Factors and Outcomes.

From GI Signals issue №18: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Pancreas/Biliary retrospective · n=984 · Nov 1, 2026 · Liver International · IF 6.7

Screening for Biliary Dysplasia Using Brush Cytology in PSC: Prevalence, Risk Factors and Outcomes.

New evidencecholangiocarcinomabiliary strictureERCPbiomarker
Clinical takeawayIn this 984-patient ERC cohort a negative brush was reassuring, but reported sensitivity of brush cytology varies widely (8% to 89%); the combined ERC-IgG4 score is a proposed tool for tailoring surveillance that the authors say may help.
What it foundBrush cytology had a negative predictive value of 0.99 for excluding cholangiocarcinoma in PSC patients.
ContextCurrent guidelines recommend annual surveillance via ultrasound or MRI/MRCP for PSC, but brush cytology offers a high negative predictive value (0.99) for excluding CCA, potentially refining surveillance strategies in select cases.
Emergingsuggested applicable standard· AASLD 2023 (Bowlus et al., Hepatology 77:659-702) practice guidance on PSC and cholangiocarcinoma, supersedes AASLD 2010; alongside EASL 2022 sclerosing cholangitis guideline

Diagnose PSC with high-quality MRCP as the reference-standard imaging (avoid ERCP for diagnostic purposes; if MRCP findings are equivocal, repeat MRCP rather than proceeding to ERCP), reserving ERCP for therapeutic intervention, and exclude secondary sclerosing cholangitis/IgG4-related disease. … Perform annual abdominal MRI/MRCP with or without serum CA19-9 for cholangiocarcinoma/gallbladder-cancer surveillance in adults with large-duct PSC (not recommended under age 18 or in small-duct PSC). …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Diagnose PSC with high-quality MRCP as the reference-standard imaging (avoid ERCP for diagnostic purposes; if MRCP findings are equivocal, repeat MRCP rather than proceeding to ERCP), reserving ERCP for therapeutic intervention, and exclude secondary sclerosing cholangitis/IgG4-related disease. No disease-modifying therapy is proven to alter transplant-free survival, but moderate-dose UDCA (13-23 mg/kg/day) may now be considered and continued in patients not enrolled in or eligible for a clinical trial if it produces a meaningful improvement in alkaline phosphatase (GGT in children) and/or symptoms by 12 months, discontinuing if no response; high-dose UDCA remains contraindicated. Perform annual abdominal MRI/MRCP with or without serum CA19-9 for cholangiocarcinoma/gallbladder-cancer surveillance in adults with large-duct PSC (not recommended under age 18 or in small-duct PSC). Manage gallbladder polyps by size, cholecystectomy for polyps >8 mm, ultrasound surveillance every 6 months for polyps ≤8 mm, rather than referring every polyp. For colorectal surveillance, begin surveillance colonoscopy at the time of PSC-IBD diagnosis (or at age 15 for childhood-onset disease) and repeat at 1-2 year intervals; in PSC without IBD, perform a diagnostic colonoscopy at PSC diagnosis and repeat every 5 years if IBD is not found. Evaluate dominant strictures with brush cytology plus FISH (± cholangioscopy) before/at balloon dilation, repeating ERCP with sampling in 3 months if cytology is suspicious regardless of FISH result. Treat recurrent cholangitis and cholestatic pruritus, maintain bone health, and refer for transplant evaluation for decompensation, intractable pruritus, recurrent bacterial cholangitis, or early-stage CCA per Mayo protocol.

AASLD 2023 (Bowlus et al., Hepatology 77:659-702) practice guidance on PSC and cholangiocarcinoma, supersedes AASLD 2010; alongside EASL 2022 sclerosing cholangitis guideline · reviewed 2026-07-24 ↗
Färkkilä M … Arola J · Liver International : Official Journal of the International Association for the Study of the Liver · IF 6.7 · PubMed ↗Permalink
← Read the whole of issue №18 Every paper GI Signals surfaces gets a page like this one. All issues